Division of Endocrinology and Metabolism, Georgetown University Medical Center, Washington, District of Columbia 20007, USA.
Thyroid. 2011 Aug;21(8):821-7. doi: 10.1089/thy.2011.0029. Epub 2011 Jul 13.
Body weight (BW) and age have been shown to affect the dose of levothyroxine (LT(4)) that results in normalization of serum thyroid-stimulating hormone (TSH) in hypothyroid patients. Our objective was to determine whether gender, menstrual status, and ideal BW (IBW) also affect the LT(4) dose required to achieve a serum TSH within the normal range.
We retrospectively reviewed the charts of patients being treated for primary hypothyroidism who had TSH values within a normal range. We selected patients aged 18-85 years who were taking LT(4) without any confounding medications, and who had no serious chronic conditions. Their LT(4) doses, referred to here as LT(4) dose requirements, based on both BW and IBW were documented. The relationship between gender, menstrual status, age, serum TSH concentrations, and the degree of overweight on LT(4) dose requirements were determined using multivariate analyses.
Women were significantly more overweight than men (ratio of BW/IBW was 1.35 for women vs. 1.17 for men, p <0.0001). LT(4) requirements based on BW did not differ by gender when age was included in the model. However, when degree of overweight was also included, men required lower LT(4) doses than both premenopausal women (1.34 μg/kg vs. 1.51 μg/kg, p = 0.038) and menopausal women (1.34 μg/kg vs. 1.49 μg/kg, p = 0.023). When examining IBW using a model incorporating age, men also required lower LT(4) doses than both premenopausal women (1.64 μg/kg vs. 1.92 μg/kg, p = 0.0033) and menopausal women (1.64 μg/kg vs. 1.90 μg/kg, p = 0.0024). Serum TSH concentrations were not significantly different in any of the gender groups. There was no relationship between serum TSH and either age or BW. The initial serum TSH concentration was by design with the normal range, but the concentration within that range was not a significant predictor of the LT(4) replacement dose in any of the models.
In contrast to previous studies suggesting that age affects LT(4) replacement requirements, we found that age-based differences in doses are secondary to differences in BW and gender. In addition, in contrast to prior studies showing that lean body mass, but not gender, affected LT(4) dose, we instead found a significant impact of gender. Gender-based differences in dose requirement only became apparent either when IBW was used to correct for the dose or when degree of overweight was included in the model. Gender differences in LT(4) dose requirement exist, but are masked unless gender-based differences in degree of overweight are also considered.
体重(BW)和年龄已被证明会影响左旋甲状腺素(LT(4))的剂量,从而使甲状腺刺激激素(TSH)在甲状腺功能减退症患者中恢复正常。我们的目的是确定性别、月经状况和理想体重(IBW)是否也会影响达到血清 TSH 正常范围内所需的 LT(4)剂量。
我们回顾性地审查了正在接受原发性甲状腺功能减退症治疗且 TSH 值在正常范围内的患者的病历。我们选择了年龄在 18-85 岁之间、正在服用 LT(4)且没有任何混杂药物、没有严重慢性疾病的患者。记录了他们的 LT(4)剂量,这里称为 LT(4)剂量需求,根据 BW 和 IBW 进行了记录。使用多元分析确定了性别、月经状况、年龄、血清 TSH 浓度和超重程度与 LT(4)剂量需求之间的关系。
女性的超重程度明显高于男性(女性的 BW/IBW 比值为 1.35,男性为 1.17,p <0.0001)。当在模型中包含年龄时,性别对基于 BW 的 LT(4)需求没有影响。然而,当也包括超重程度时,男性所需的 LT(4)剂量低于绝经前女性(1.34μg/kg 比 1.51μg/kg,p=0.038)和绝经后女性(1.34μg/kg 比 1.49μg/kg,p=0.023)。当使用包含年龄的模型检查 IBW 时,男性所需的 LT(4)剂量也低于绝经前女性(1.64μg/kg 比 1.92μg/kg,p=0.0033)和绝经后女性(1.64μg/kg 比 1.90μg/kg,p=0.0024)。在任何性别组中,血清 TSH 浓度均无显著差异。血清 TSH 与年龄或 BW 之间没有关系。初始血清 TSH 浓度设计在正常范围内,但在任何模型中,该范围内的浓度均不是 LT(4)替代剂量的显著预测因子。
与之前表明年龄影响 LT(4)替代需求的研究相反,我们发现剂量的年龄差异是由 BW 和性别差异引起的。此外,与先前表明瘦体重(而不是性别)会影响 LT(4)剂量的研究相反,我们发现性别会产生重大影响。只有当使用 IBW 来校正剂量或当模型中包含超重程度时,才会出现剂量要求的性别差异。LT(4)剂量需求存在性别差异,但除非同时考虑基于性别的超重程度差异,否则这些差异将被掩盖。